Neurocrine Biosciences | Bienes



Assets Cambio Fecha
AbbVie USD 135.16B 8.26B 2024-12
Acadia Pharmaceuticals USD 1.19B 210.89M 2024-12
Agios Pharmaceuticals USD 1.66B 128.6M 2024-12
ALKERMES USD 2.06B 99.72M 2024-12
Alnylam Pharmaceuticals USD 4.24B 34.94M 2024-12
Amgen USD 91.84B 956M 2024-12
Biogen USD 28.05B 263.9M 2024-12
BioMarin Pharmaceutical USD 6.99B 137.74M 2024-12
Cytokinetics USD 1.4B 34.39M 2024-12
Dynavax Technologies USD 986.26M 75.73M 2024-12
Exelixis USD 2.95B 12.59M 2025-01
Gilead Sciences USD 59B 4.47B 2024-12
Halozyme Therapeutics USD 2.06B 54.55M 2024-12
Incyte USD 5.44B 431.89M 2024-12
Intra Cellular Therapies USD 1.37B 42.47M 2024-12
Ionis Pharmaceuticals USD 3B 77.42M 2024-12
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Pfizer USD 213.4B 6.08B 2024-12
Prothena USD 547.11M 48.15M 2024-12
Regeneron Pharmaceuticals USD 37.76B 317.5M 2024-12
Repligen USD 2.83B 31.28M 2024-09
Sarepta Therapeutics USD 3.96B 363.24M 2024-12
Teva Pharmaceutical Industries USD 39.33B 2.43B 2024-12
Ultragenyx Pharmaceutical USD 1.5B 34.91M 2024-12
Vertex Pharmaceuticals USD 22.53B 293M 2024-12



Neurocrine Biosciences Bienes - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.